[1]
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein, Textbook of Diabetes. John Wiley, 2016 [Online]. Available: https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056
[2]
‘Type 2 diabetes in adults: management | Guidance and guidelines | NICE’ [Online]. Available: https://www.nice.org.uk/guidance/ng28
[3]
‘Resources and tools’. [Online]. Available: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html
[4]
‘Resources and tools’. [Online]. Available: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html
[5]
‘Resources and tools’. [Online]. Available: http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html
[6]
W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
[7]
Anthony H. Barnett, Jenny Grice, New Mechanisms in Glucose Control. BMJ Books; 1 edition, 2013 [Online]. Available: http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133
[8]
‘WHO 2011 Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus’. [Online]. Available: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/
[9]
M. A. Atkinson, ‘The Pathogenesis and Natural History of Type 1 Diabetes’, Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 11, pp. a007641–a007641, Nov. 2012, doi: 10.1101/cshperspect.a007641.
[10]
V. T. Samuel and G. I. Shulman, ‘Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links’, Cell, vol. 148, no. 5, pp. 852–871, Mar. 2012, doi: 10.1016/j.cell.2012.02.017.
[11]
Beverley M Shields, ‘Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature’, BMJ Open, vol. 5, no. 11, 2015, doi: doi: 10.1136/bmjopen-2015-009088. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic
[12]
F. Zaccardi, D. R. Webb, T. Yates, and M. J. Davies, ‘Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective’, Postgraduate Medical Journal, vol. 92, no. 1084, pp. 63–69, Feb. 2016, doi: 10.1136/postgradmedj-2015-133281.
[13]
A. G. Jones and A. T. Hattersley, ‘The clinical utility of C-peptide measurement in the care of patients with diabetes’, Diabetic Medicine, vol. 30, no. 7, pp. 803–817, Jul. 2013, doi: 10.1111/dme.12159.
[14]
B. T. Srinivasan, J. Jarvis, K. Khunti, and M. J. Davies, ‘Recent advances in the management of type 2 diabetes mellitus: a review’, Postgraduate Medical Journal, vol. 84, no. 996, pp. 524–531, Oct. 2008, doi: 10.1136/pgmj.2008.067918.
[15]
K. C. Copeland et al., ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’, PEDIATRICS, vol. 131, no. 2, pp. 364–382, Feb. 2013, doi: 10.1542/peds.2012-3494.
[16]
Celia G. Walker, ‘Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk’, PLoS ONE, vol. 10, no. 7, 2015, doi: doi: 10.1371/journal.pone.0131681. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496090/
[17]
S. Chatterjee and M. Davies, ‘Type 2 diabetes: recent advances in diagnosis and management’, Prescriber, vol. 26, no. 10, pp. 15–21, May 2015, doi: 10.1002/psb.1355.
[18]
F. Ismail-Beigi, ‘Glycemic Management of Type 2 Diabetes Mellitus’, New England Journal of Medicine, vol. 366, no. 14, pp. 1319–1327, Apr. 2012, doi: 10.1056/NEJMcp1013127.
[19]
D. M. Nathan et al., ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, vol. 29, no. 8, pp. 1963–1972, Aug. 2006, doi: 10.2337/dc06-9912.
[20]
B. T. Srinivasan and M. Davies, ‘Glycaemic management of type 2 diabetes’, Medicine, vol. 42, no. 12, pp. 711–717, Dec. 2014, doi: 10.1016/j.mpmed.2014.09.011.
[21]
S M Attard, ‘Implications of iron deficiency/anemia on the classification of diabetes using HbA1c’, Nutrition & Diabetes, vol. 5, no. 6, 2015, doi: doi: 10.1038/nutd.2015.16. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/
[22]
S. S. Schwartz, S. Epstein, B. E. Corkey, S. F. A. Grant, J. R. Gavin, and R. B. Aguilar, ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’, Diabetes Care, vol. 39, no. 2, pp. 179–186, Feb. 2016, doi: 10.2337/dc15-1585.
[23]
C. J. Nolan, N. B. Ruderman, S. E. Kahn, O. Pedersen, and M. Prentki, ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’, Diabetes, vol. 64, no. 3, pp. 673–686, Mar. 2015, doi: 10.2337/db14-0694.
[24]
C. V. Rizos, A. Kei, and M. S. Elisaf, ‘The current role of thiazolidinediones in diabetes management’, Archives of Toxicology, vol. 90, no. 8, pp. 1861–1881, Aug. 2016, doi: 10.1007/s00204-016-1737-4.
[25]
S. E. Nissen and K. Wolski, ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’, New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, Jun. 2007, doi: 10.1056/NEJMoa072761.
[26]
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’. 4AD [Online]. Available: https://www.youtube.com/watch?v=AhhWTmEFuag
[27]
‘[ARCHIVED CONTENT] Medicines management: Everybody’s business : Department of Health - Publications and statistics’. [Online]. Available: http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200
[28]
A. F. Vloemans et al., ‘Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study’, Diabetic Medicine, vol. 34, no. 10, pp. 1470–1476, Oct. 2017, doi: 10.1111/dme.13429.
[29]
S. Sivasubramaniyam, S. A. Amiel, and P. Choudhary, ‘Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range’, Diabetic Medicine, vol. 34, no. 10, pp. 1456–1460, Oct. 2017, doi: 10.1111/dme.13438.
[30]
W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
[31]
S. E. Inzucchi et al., ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’, Diabetes Care, vol. 38, no. 1, pp. 140–149, Jan. 2015, doi: 10.2337/dc14-2441.
[32]
B. Ryder et al., ‘ABCD position statement on GLP-1 based therapies and pancreatic damage’, Practical Diabetes, vol. 30, no. 9, pp. 388–391, Nov. 2013, doi: 10.1002/pdi.1816.
[33]
A. J. Garber et al., ‘Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial’, The Lancet, vol. 379, no. 9825, pp. 1498–1507, Apr. 2012, doi: 10.1016/S0140-6736(12)60205-0.
[34]
S. Gururaj Setty, W. Crasto, J. Jarvis, K. Khunti, and M. J. Davies, ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, vol. 92, no. 1085, pp. 152–164, Mar. 2016, doi: 10.1136/postgradmedj-2015-133716.
[35]
Z. Z. Htike, F. Zaccardi, S. Chatterjee, K. Khunti, and M. J. Davies, ‘Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care’, British Journal of Diabetes, vol. 16, no. 3, Sep. 2016, doi: 10.15277/bjd.2016.091.
[36]
M. J. Davies and S. Chatterjee, ‘Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care’, Nature Reviews Endocrinology, vol. 13, no. 6, pp. 317–318, Apr. 2017, doi: 10.1038/nrendo.2017.41.
[37]
S. C. L. Gough, S. Harris, V. Woo, and M. Davies, ‘Insulin degludec: overview of a novel ultra long-acting basal insulin’, Diabetes, Obesity and Metabolism, vol. 15, no. 4, pp. 301–309, Apr. 2013, doi: 10.1111/dom.12052.
[38]
S. G. Ashwell et al., ‘Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes’, Diabetic Medicine, vol. 23, no. 3, pp. 285–292, Mar. 2006, doi: 10.1111/j.1464-5491.2005.01781.x.
[39]
R. G. Bretzel, U. Nuber, W. Landgraf, D. R. Owens, C. Bradley, and T. Linn, ‘Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial’, The Lancet, vol. 371, no. 9618, pp. 1073–1084, Mar. 2008, doi: 10.1016/S0140-6736(08)60485-7.
[40]
M. M. Funnell, ‘Overcoming Barriers to the Initiation of Insulin Therapy’, Clinical Diabetes, vol. 25, no. 1, pp. 36–38, Jan. 2007, doi: 10.2337/diaclin.25.1.36.
[41]
A. J. Garber et al., ‘Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)’, Diabetes, Obesity and Metabolism, vol. 8, no. 1, pp. 58–66, Jan. 2006, doi: 10.1111/j.1463-1326.2005.00563.x.
[42]
S. C. L. Gough, ‘A review of human and analogue insulin trials’, Diabetes Research and Clinical Practice, vol. 77, no. 1, pp. 1–15, Jul. 2007, doi: 10.1016/j.diabres.2006.10.015.
[43]
A. J. Garber, R. Ligthelm, J. S. Christiansen, and A. Liebl, ‘Premixed insulin treatment for type 2 diabetes: analogue or human?’, Diabetes, Obesity and Metabolism, vol. 9, no. 5, pp. 630–639, Sep. 2007, doi: 10.1111/j.1463-1326.2006.00654.x.
[44]
S. R. Heller et al., ‘Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes’, Diabetic Medicine, vol. 21, no. 7, pp. 769–775, Jul. 2004, doi: 10.1111/j.1464-5491.2004.01244.x.
[45]
K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, and P. Home, ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’, Diabetes Care, vol. 29, no. 6, pp. 1269–1274, Jun. 2006, doi: 10.2337/dc05-1365.
[46]
R. R. Holman et al., ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’, New England Journal of Medicine, vol. 357, no. 17, pp. 1716–1730, Oct. 2007, doi: 10.1056/NEJMoa075392.
[47]
R. R. Holman and R. C. Turner, ‘A Practical Guide to Basal and Prandial Insulin Therapy’, Diabetic Medicine, vol. 2, no. 1, pp. 45–53, Jan. 1985, doi: 10.1111/j.1464-5491.1985.tb00592.x.
[48]
K. Horvath et al., ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD005613.pub3
[49]
M. Marre et al., ‘Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)’, Diabetic Medicine, vol. 26, no. 3, pp. 268–278, Mar. 2009, doi: 10.1111/j.1464-5491.2009.02666.x.
[50]
L. A. Young and J. B. Buse, ‘GLP-1 receptor agonists and basal insulin in type 2 diabetes’, The Lancet, vol. 384, no. 9961, pp. 2180–2181, Dec. 2014, doi: 10.1016/S0140-6736(14)61409-4.
[51]
M. Diamant et al., ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.
[52]
S. Gururaj Setty, W. Crasto, J. Jarvis, K. Khunti, and M. J. Davies, ‘New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes’, Postgraduate Medical Journal, vol. 92, no. 1085, pp. 152–164, Mar. 2016, doi: 10.1136/postgradmedj-2015-133716.
[53]
J. Rosenstock et al., ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)’, Diabetes Care, vol. 36, no. 10, pp. 2945–2951, Oct. 2013, doi: 10.2337/dc12-2709.
[54]
M. Evans, P. M. Schumm-Draeger, J. Vora, and A. B. King, ‘A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations’, Diabetes, Obesity and Metabolism, vol. 13, no. 8, pp. 677–684, Aug. 2011, doi: 10.1111/j.1463-1326.2011.01395.x.
[55]
P. D. Home, ‘The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences’, Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 780–788, Sep. 2012, doi: 10.1111/j.1463-1326.2012.01580.x.
[56]
B. Richter and G. Neises, ‘“Human” insulin versus animal insulin in people with diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD003816.pub2
[57]
S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. DeVries, ‘Insulin detemir versus insulin glargine for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD006383.pub2
[58]
H. Yki-Järvinen et al., ‘Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study’, Diabetologia, vol. 49, no. 3, pp. 442–451, Mar. 2006, doi: 10.1007/s00125-005-0132-0.
[59]
B. Zinman et al., ‘Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial’, The Lancet, vol. 377, no. 9769, pp. 924–931, Mar. 2011, doi: 10.1016/S0140-6736(10)62305-7.
[60]
K. Horvath et al., ‘Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD005613.pub3
[61]
J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, ‘A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes’, Diabetologia, vol. 51, no. 3, pp. 408–416, Mar. 2008, doi: 10.1007/s00125-007-0911-x.
[62]
P. Raskin et al., ‘Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs’, Diabetes Care, vol. 28, no. 2, pp. 260–265, Feb. 2005, doi: 10.2337/diacare.28.2.260.
[63]
M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, and R. Gomis, ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine’, Diabetes Care, vol. 28, no. 6, pp. 1282–1288, Jun. 2005, doi: 10.2337/diacare.28.6.1282.
[64]
Z. Z. Htike, F. Zaccardi, D. Papamargaritis, D. R. Webb, K. Khunti, and M. J. Davies, ‘Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis’, Diabetes, Obesity and Metabolism, vol. 19, no. 4, pp. 524–536, Apr. 2017, doi: 10.1111/dom.12849.
[65]
Z. Z. Htike, F. Zaccardi, D. Papamargaritis, D. R. Webb, K. Khunti, and M. J. Davies, ‘Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis’, Diabetes, Obesity and Metabolism, vol. 19, no. 4, pp. 524–536, Apr. 2017, doi: 10.1111/dom.12849.
[66]
R. E. Amori, J. Lau, and A. G. Pittas, ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’, JAMA, vol. 298, no. 2, Jul. 2007, doi: 10.1001/jama.298.2.194.
[67]
J. B. Buse et al., ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’, Diabetes Care, vol. 33, no. 6, pp. 1255–1261, Jun. 2010, doi: 10.2337/dc09-1914.
[68]
J. B. Buse et al., ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’, Annals of Internal Medicine, vol. 154, no. 2, Jan. 2011, doi: 10.7326/0003-4819-154-2-201101180-00300.
[69]
J. B. Buse et al., ‘Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)’, The Lancet, vol. 374, no. 9683, pp. 39–47, Jul. 2009, doi: 10.1016/S0140-6736(09)60659-0.
[70]
M. A. Nauck and J. J. Meier, ‘The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions’, The Lancet Diabetes & Endocrinology, vol. 4, no. 6, pp. 525–536, Jun. 2016, doi: 10.1016/S2213-8587(15)00482-9.
[71]
S. P. Marso et al., ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.
[72]
‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 18, pp. 1797–1799, Nov. 2016, doi: 10.1056/NEJMc1611289.
[73]
H. Courtney, R. Nayar, C. Rajeswaran, and R. Jandhyala, ‘Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. Volume 10, pp. 79–87, Mar. 2017, doi: 10.2147/DMSO.S126763.
[74]
M. E. Rotz, V. S. Ganetsky, S. Sen, and T. F. Thomas, ‘Implications of incretin-based therapies on cardiovascular disease’, International Journal of Clinical Practice, vol. 69, no. 5, pp. 531–549, May 2015, doi: 10.1111/ijcp.12572.
[75]
P. A. Levin, H. Nguyen, E. Wittbrodt, and S. C. Kim, ‘Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. Volume 10, pp. 123–139, Apr. 2017, doi: 10.2147/DMSO.S130834.
[76]
M. C. Riddle et al., ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)’, Diabetes Care, vol. 36, no. 9, pp. 2489–2496, Sep. 2013, doi: 10.2337/dc12-2454.
[77]
K. M. Dungan et al., ‘Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial’, The Lancet, vol. 384, no. 9951, pp. 1349–1357, Oct. 2014, doi: 10.1016/S0140-6736(14)60976-4.
[78]
M. Nauck, R. S. Weinstock, G. E. Umpierrez, B. Guerci, Z. Skrivanek, and Z. Milicevic, ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’, Diabetes Care, vol. 37, no. 8, pp. 2149–2158, Aug. 2014, doi: 10.2337/dc13-2761.
[79]
‘Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials- ClinicalKey’. [Online]. Available: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null
[80]
‘Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com’. [Online]. Available: http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level
[81]
M. Davies, D. Dahl, T. Heise, J. Kiljanski, and C. Mathieu, ‘Introduction of biosimilar insulins in Europe’, Diabetic Medicine, vol. 34, no. 10, pp. 1340–1353, Oct. 2017, doi: 10.1111/dme.13400.
[82]
W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
[83]
‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’, Diabetes Care, vol. 38, no. Supplement_1, pp. S4–S4, Jan. 2015, doi: 10.2337/dc15-S003.
[84]
‘Minimizing Hypoglycemia in Diabetes: Table 1’, Diabetes Care, vol. 38, no. 8, pp. 1583–1591, Aug. 2015, doi: 10.2337/dc15-0279.
[85]
J. Grammes, W. Stock, C. G. Mann, E. M. Flynn, and T. Kubiak, ‘Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus’, Diabetic Medicine, Aug. 2017, doi: 10.1111/dme.13506.
[86]
C. Carver, ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’, The Diabetes Educator, vol. 32, no. 6, pp. 910–917, Nov. 2006, doi: 10.1177/0145721706294259.
[87]
S. Mäkimattila, K. Nikkilä, and H. Yki-Järvinen, ‘Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus’, Diabetologia, vol. 42, no. 4, pp. 406–412, Mar. 1999, doi: 10.1007/s001250051172.
[88]
M. Villani, B. de Courten, and S. Zoungas, ‘Emergency treatment of hypoglycaemia: a guideline and evidence review’, Diabetic Medicine, vol. 34, no. 9, pp. 1205–1211, Sep. 2017, doi: 10.1111/dme.13379.
[89]
R. K. Simmons et al., ‘A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study’, Health Technology Assessment, vol. 20, no. 64, pp. 1–86, Aug. 2016, doi: 10.3310/hta20640.
[90]
Kamlesh Khunti, ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’, PLoS ONE, vol. 10, no. 9, 2015, doi: doi: 10.1371/journal.pone.0135702. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic
[91]
L. Tao et al., ‘Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial’, Diabetic Medicine, vol. 32, no. 7, pp. 907–919, Jul. 2015, doi: 10.1111/dme.12711.
[92]
L. J. Gray, K. Khunti, E. G. Wilmot, T. Yates, and M. J. Davies, ‘External validation of two diabetes risk scores in a young UK South Asian population’, Diabetes Research and Clinical Practice, vol. 104, no. 3, pp. 451–458, Jun. 2014, doi: 10.1016/j.diabres.2014.03.018.
[93]
L. J. Gray et al., ‘Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance’, Diabetologia, vol. 55, no. 12, pp. 3238–3244, Dec. 2012, doi: 10.1007/s00125-012-2725-8.
[94]
B. C. Johnston et al., ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’, JAMA, vol. 312, no. 9, Sep. 2014, doi: 10.1001/jama.2014.10397.
[95]
S. Steven et al., ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’, Diabetes Care, vol. 39, no. 5, pp. 808–815, May 2016, doi: 10.2337/dc15-1942.
[96]
S. Steven and R. Taylor, ‘Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes’, Diabetic Medicine, vol. 32, no. 9, pp. 1149–1155, Sep. 2015, doi: 10.1111/dme.12722.
[97]
S. J. Persaud and P. M. Jones, ‘A Wake-up Call for Type 2 Diabetes?’, New England Journal of Medicine, vol. 375, no. 11, pp. 1090–1092, Sep. 2016, doi: 10.1056/NEJMcibr1607950.
[98]
K. K. Dhatariya, C. Skedgel, and R. Fordham, ‘The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use’, Diabetic Medicine, vol. 34, no. 10, pp. 1361–1366, Oct. 2017, doi: 10.1111/dme.13427.
[99]
W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
[100]
M. J. Davies et al., ‘Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial’, BMJ, vol. 336, no. 7642, pp. 491–495, Mar. 2008, doi: 10.1136/bmj.39474.922025.BE.
[101]
B. Gallwitz et al., ‘2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial’, The Lancet, vol. 380, no. 9840, pp. 475–483, Aug. 2012, doi: 10.1016/S0140-6736(12)60691-6.
[102]
M. Diamant et al., ‘Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial’, The Lancet, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.
[103]
S. P. Marso et al., ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.
[104]
C. Wanner et al., ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 4, pp. 323–334, Jul. 2016, doi: 10.1056/NEJMoa1515920.
[105]
‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 18, pp. 1799–1802, Nov. 2016, doi: 10.1056/NEJMc1611290.
[106]
M. A. Bethel et al., ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)’, Diabetes Care, Jan. 2017, doi: 10.2337/dc16-1135.
[107]
Merlin C. Thomas, ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’, Diabetes Therapy, vol. 7, no. 3, 2016, doi: doi: 10.1007/s13300-016-0189-4. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/
[108]
Paul Craddy, ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’, Diabetes Therapy, vol. 5, no. 1, 2014, doi: doi: 10.1007/s13300-014-0061-3. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/
[109]
W. L. Bennett et al., ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’, Annals of Internal Medicine, vol. 154, no. 9, May 2011, doi: 10.7326/0003-4819-154-9-201105030-00336.
[110]
J. B. Green et al., ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’, New England Journal of Medicine, vol. 373, no. 3, pp. 232–242, Jul. 2015, doi: 10.1056/NEJMoa1501352.
[111]
S. H. Min, J.-H. Yoon, S. Hahn, and Y. M. Cho, ‘Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis’, Diabetes/Metabolism Research and Reviews, vol. 33, no. 1, Jan. 2017, doi: 10.1002/dmrr.2818.
[112]
M. Capehorn et al., ‘Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia )’, Diabetic Medicine, Mar. 2017, doi: 10.1111/dme.13357.
[113]
C. F. Deacon and H. E. Lebovitz, ‘Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas’, Diabetes, Obesity and Metabolism, vol. 18, no. 4, pp. 333–347, Apr. 2016, doi: 10.1111/dom.12610.
[114]
B. M. Mishriky, D. M. Cummings, and R. J. Tanenberg, ‘The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis’, Diabetes Research and Clinical Practice, vol. 109, no. 2, pp. 378–388, Aug. 2015, doi: 10.1016/j.diabres.2015.05.025.
[115]
H. Daly et al., ‘Development of a self-management education module for those with type 2 diabetes on injectable therapies’, Practical Diabetes, vol. 32, no. 8, pp. 305–310a, Oct. 2015, doi: 10.1002/pdi.1979.
[116]
M. Nauck, ‘Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors’, Diabetes, Obesity and Metabolism, vol. 18, no. 3, pp. 203–216, Mar. 2016, doi: 10.1111/dom.12591.
[117]
C. S. S. Frandsen and S. Madsbad, ‘Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review’, Diabetic Medicine, vol. 31, no. 11, pp. 1293–1300, Nov. 2014, doi: 10.1111/dme.12561.
[118]
M. Hadjiconstantinou et al., ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’, Journal of Medical Internet Research, vol. 18, no. 10, Oct. 2016, doi: 10.2196/jmir.5991.
[119]
D. Young-Hyman, M. de Groot, F. Hill-Briggs, J. S. Gonzalez, K. Hood, and M. Peyrot, ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’, Diabetes Care, vol. 40, no. 2, p. 287.1-287, Feb. 2017, doi: 10.2337/dc17-er02.
[120]
M. Tanner, ‘Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia’, Annals of Internal Medicine, vol. 165, no. 4, Aug. 2016, doi: 10.7326/ACPJC-2016-165-4-020.
[121]
B. M. Mishriky, D. M. Cummings, and R. J. Tanenberg, ‘The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis’, Diabetes Research and Clinical Practice, vol. 109, no. 2, pp. 378–388, Aug. 2015, doi: 10.1016/j.diabres.2015.05.025.
[122]
C. J. Bailey, J. L. Gross, A. Pieters, A. Bastien, and J. F. List, ‘Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial’, The Lancet, vol. 375, no. 9733, pp. 2223–2233, Jun. 2010, doi: 10.1016/S0140-6736(10)60407-2.
[123]
M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. P. Stein, ‘Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial’, Diabetes, Obesity and Metabolism, vol. 9, no. 2, pp. 194–205, Mar. 2007, doi: 10.1111/j.1463-1326.2006.00704.x.
[124]
S. P. Marso et al., ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’, New England Journal of Medicine, vol. 375, no. 19, pp. 1834–1844, Nov. 2016, doi: 10.1056/NEJMoa1607141.
[125]
B. Anderson, M. Funnell, and American Diabetes Association, The art of empowerment: stories and strategies for diabetes educators, 2nd ed. Alexandria, Va: American Diabetes Association, 2005.
[126]
W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
[127]
P. R. Schauer et al., ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, vol. 366, no. 17, pp. 1567–1576, Apr. 2012, doi: 10.1056/NEJMoa1200225.
[128]
D. R. Leff and D. Heath, ‘Surgery for obesity in adulthood’, BMJ, vol. 339, no. sep22 1, pp. b3402–b3402, Sep. 2009, doi: 10.1136/bmj.b3402.
[129]
L. Sjöström et al., ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’, New England Journal of Medicine, vol. 351, no. 26, pp. 2683–2693, Dec. 2004, doi: 10.1056/NEJMoa035622.
[130]
P. R. Schauer et al., ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’, New England Journal of Medicine, vol. 376, no. 7, pp. 641–651, Feb. 2017, doi: 10.1056/NEJMoa1600869.
[131]
P. R. Schauer et al., ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’, New England Journal of Medicine, vol. 366, no. 17, pp. 1567–1576, Apr. 2012, doi: 10.1056/NEJMoa1200225.
[132]
J. Brown et al., ‘Lifestyle interventions for the treatment of women with gestational diabetes’, in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: http://doi.wiley.com/10.1002/14651858.CD011970.pub2
[133]
Kenneth Hodson, ‘Gestational diabetes: emerging concepts in pathophysiology’, Obstetric Medicine, vol. 3, no. 4, 2010, doi: doi: 10.1258/om.2010.100025. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic
[134]
Latika Sahu, ‘Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy’, Obstetric Medicine, vol. 2, no. 4, 2009, doi: doi: 10.1258/om.2009.080049. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic
[135]
C. Moreno-Castilla, D. Mauricio, and M. Hernandez, ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’, Current Diabetes Reports, vol. 16, no. 4, Apr. 2016, doi: 10.1007/s11892-016-0717-7.
[136]
‘Postnatal testing following gestational diabetes- ClinicalKey’. [Online]. Available: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null
[137]
K. I. Birkeland, ‘Hyperglycaemia in pregnancy: still a lot to learn’, The Lancet Diabetes & Endocrinology, vol. 3, no. 10, pp. 752–753, Oct. 2015, doi: 10.1016/S2213-8587(15)00282-X.
[138]
Rinki Murphy, ‘Monogenic diabetes and pregnancy’, Obstetric Medicine, vol. 8, no. 3, 2015, doi: doi: 10.1177/1753495X15590713. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/
[139]
Z. A. Stewart et al., ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’, New England Journal of Medicine, vol. 375, no. 7, pp. 644–654, Aug. 2016, doi: 10.1056/NEJMoa1602494.
[140]
J. S. Yeh, R. F. Kushner, and G. D. Schiff, ‘Obesity and Management of Weight Loss’, New England Journal of Medicine, vol. 375, no. 12, pp. 1187–1189, Sep. 2016, doi: 10.1056/NEJMclde1515935.
[141]
‘Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care’. [Online]. Available: http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview
[142]
Henson, Joseph, ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’, Nov. 2014 [Online]. Available: https://lra.le.ac.uk/handle/2381/32505
[143]
W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745
[144]
P. Srinivasan, G. C. Huang, S. A. Amiel, and N. D. Heaton, ‘Islet cell transplantation’, Postgraduate Medical Journal, vol. 83, no. 978, pp. 224–229, Apr. 2007, doi: 10.1136/pgmj.2006.053447.
[145]
P. Choudhary, N. R. Parrott, L. Birtles, and M. K. Rutter, ‘Islet cell transplantation: current status in the UK (2012)’, Practical Diabetes, vol. 29, no. 7, pp. 280–285, Sep. 2012, doi: 10.1002/pdi.1707.
[146]
Amy Kennedy, ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’, PLoS ONE, vol. 8, no. 3, 2013, doi: doi: 10.1371/journal.pone.0058861. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/
[147]
M. Chimen, A. Kennedy, K. Nirantharakumar, T. T. Pang, R. Andrews, and P. Narendran, ‘What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review’, Diabetologia, vol. 55, no. 3, pp. 542–551, Mar. 2012, doi: 10.1007/s00125-011-2403-2.
[148]
D. Umpierre, ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes’, JAMA, vol. 305, no. 17, May 2011, doi: 10.1001/jama.2011.576.
[149]
L. Avery, D. Flynn, A. van Wersch, F. F. Sniehotta, and M. I. Trenell, ‘Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions’, Diabetes Care, vol. 35, no. 12, pp. 2681–2689, Dec. 2012, doi: 10.2337/dc11-2452.
[150]
V. W. Barry, M. Baruth, M. W. Beets, J. L. Durstine, J. Liu, and S. N. Blair, ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’, Progress in Cardiovascular Diseases, vol. 56, no. 4, pp. 382–390, Jan. 2014, doi: 10.1016/j.pcad.2013.09.002.
[151]
L. Qin, M. J. Knol, E. Corpeleijn, and R. P. Stolk, ‘Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data’, European Journal of Epidemiology, vol. 25, no. 1, pp. 5–12, Jan. 2010, doi: 10.1007/s10654-009-9395-y.
[152]
I.-M. Lee, ‘Physical Activity and Weight Gain Prevention’, JAMA, vol. 303, no. 12, Mar. 2010, doi: 10.1001/jama.2010.312.
[153]
John M Jakicic, ‘Physical activity considerations for the treatment and prevention of obesity’, The American Journal of Clinical Nutrition, vol. 82, no. 1, pp. 226S-229S, Jan. 2005 [Online]. Available: http://ajcn.nutrition.org/content/82/1/226S
[154]
I. Heinonen et al., ‘Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study’, BMJ Open, vol. 3, no. 6, May 2013, doi: 10.1136/bmjopen-2013-002901.
[155]
J. F. Sallis et al., ‘Progress in physical activity over the Olympic quadrennium’, The Lancet, vol. 388, no. 10051, pp. 1325–1336, Sep. 2016, doi: 10.1016/S0140-6736(16)30581-5.
[156]
Y. A. W. Hartman, H. J. Jansen, M. T. E. Hopman, C. J. Tack, and D. H. J. Thijssen, ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’, Diabetes Care, vol. 40, no. 9, pp. e120–e121, Sep. 2017, doi: 10.2337/dc17-0787.
[157]
Michael Riddell, ‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’, Journal of diabetes science and technology (Online), vol. 3, no. 4, 2009, doi: doi: 10.1177/193229680900300439. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/
